Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537173 · ClinicalTrials.gov registry record
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
A clinical trial, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- 11
- Enrollment target
NCT00537173: Clinical Trial study, sponsored by Hoosier Cancer Research Network.
NCT00537173 is a clinical trial that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00537173 was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
This trial provides a unique opportunity in that it combines genomic, proteomic and pharmacogenomic assessments in patients receiving chemotherapy for advanced breast cancer. To date no other trials have analyzed gene and protein expression at the same time points in the same patient, combined with clinical outcome. Similar to previous attempts to predict response based on expression of a single gene or protein, we expect that neither genomic or proteomic profiling alone will be sufficient to optimize therapy. Rather, we expect an iterative process that combines information gleaned from both platforms, modified to avoid toxicity based on pharmacogenomics.
Interventions
- DRUG Paclitaxel
- PROCEDURE Core Biopsy
- PROCEDURE Blood Collection
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-08 |
Why NCT00537173 stopped before completion
NCT00537173 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Paclitaxel is the first listed.
NCT00537173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00537173 about?
NCT00537173 is a clinical study titled "Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer". This trial provides a unique opportunity in that it combines genomic, proteomic and pharmacogenomic assessments in patients receiving chemotherapy for advanced breast cancer. To date no other trials have analyzed gene and protein expression at the same time points in the same patient, combined with ...
What is the current status of trial NCT00537173?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2007-09. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00537173?
The interventions under investigation include: Paclitaxel (DRUG), Core Biopsy (PROCEDURE), Blood Collection (PROCEDURE), Avastin (DRUG).
Who is sponsoring clinical trial NCT00537173?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia